HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- After decades of growth efforts to reverse melanoma epidemic intensify
-
- Addition of bortezomib improved outcomes in post-ASCT relapsed multiple myeloma
- Allogeneic transplants not recommended for PNH-related thromboembolism
- BC Cancer Agency appoints president
- Chronic fatigue syndrome may be associated with increased NHL risk
- Combination regimen did not improve survival in low-grade glioma in children
- Decitabine improved response rate, may improve survival in older patients with AML
- Diabetes drug linked to increased risk for bladder cancer
- Essential thrombocythemia, myelofibrosis distinct diseases
-
- Family history increased risk for early-life non-Hodgkin’s lymphoma
- Global cancer incidence may increase 75% by 2030
- Hem/Oncs: Supreme Court ruling assures health care ‘business as usual’ will not continue
- Imaging after 1 year may not be beneficial in HL survivors
- Intensified chemotherapy regimen failed to improve outcomes in high-risk rhabdomyosarcoma
- KRAS-variant associated with breast, ovarian cancer risk
- Leader in CLL research receives memorial award
- Packed red blood cell transfusion improved sucking among neonates with anemia of prematurity
-
- Patients with, without diabetes had higher risk for major bleeding on low-dose aspirin
- PCPs in need of clinical decision-making tool for deciding to cease PSA testing in patients
- Physician joins advisory committee
- STAT3 signaling may be cause of large granular lymphocytic leukemia
- UN adopts resolutions to reduce incidence of cancer and other noncommunicable diseases
- Vorapaxar reduced hospitalization for limb ischemia, arterial revascularization in PAD patients
- ODAC supports approval of multiple myeloma drug
- FDA approves pertuzumab for patients with advanced HER-2–positive breast cancer
-
- FDA committee rejects experimental blood clot drug
- AMA: Women should be eligible for mammograms starting at age 40
- The role of PET/CT in detection of occult recurrent ovarian cancer Munir Ghesani, MD, FACNM; Kevin Holcomb, MD; Sumit Talwar, MD
- Colonoscopy by gastroenterologist reduced risk of colorectal death
- Combination treatment active, well tolerated in advanced sarcoma patients
- Cutaneous melanoma growth rate helped to predict sentinel lymph node positivity
- Early PET response predicted increased survival after chemotherapy in sarcoma patients
- Laxative-free CT colonography may be as effective as standard colonoscopy in detecting high-risk polyps
-
- Metformin may reduce breast cancer risk in older women with diabetes
- Pazopanib improved PFS in soft-tissue sarcoma
- Researchers develop model to predict distant recurrence of cervical cancer
- Specialized clinics improved in accurately detecting melanoma
- Women received less information about fertility preservation
- Addition of abiraterone to HT could eliminate tumors in some men with high-risk prostate cancer
- Childhood cancer survivors at greater risk for chronic health conditions
- Colorectal cancer resection rates increased in patients aged younger than 50 years
-
- Continuation of bevacizumab with second-line chemotherapy extended survival in patients with metastatic colorectal cancer
- DeCIDE: Addition of induction chemotherapy to chemoradiotherapy did not significantly improve OS
- Erlotinib after first-line chemotherapy did not improve PFS, OS
- Immunotherapy agent showed high response rates in three tumor types
- Intrinsic subtyping provided significant prognostic information
- Molecular analysis of NSCLC established in community hospital network
- Paclitaxel carboplatin combination improved PFS OS in women with advanced gynecologic cancer
- PARADIGM: Sequential therapy did not extend survival
-
- Squamous cell carcinoma of lung identified as distinct molecular subtype
- New guidelines recommend full-dose chemotherapy for obese cancer patients Karen Eckmann, PharmD, BCOP